share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Feb 16 05:34
Summary by Futu AI
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on 02/15/2024, according to a recent filing. The shares, valued at an aggregate market value of $1,607,176, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This planned sale follows a three-month period where Kulkarni sold 70,000 shares, generating gross proceeds of $4,275,626.
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on 02/15/2024, according to a recent filing. The shares, valued at an aggregate market value of $1,607,176, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This planned sale follows a three-month period where Kulkarni sold 70,000 shares, generating gross proceeds of $4,275,626.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.